Roswell Park Cancer Institute (RPCI) has joined the New York Genome Center (NYGC) as an Association Member to collaborate to design clinical wp-contentlications for genome sequencing in oncology.
As a leading, comprehensive national and international center for cancer research, clinical care and education, RPCI provides basic and translational research, educational programs, and multidisciplinary and compassionate patient care. RPCI also brings additional resources such as its Genomics Shared Resource, a Pathology Resource Network, Bioinformatics Shared Resource, and Data Bank and BioRepository (DBBR).
“Its unique, specialized focus on cancer research, prevention and treatment will contribute significantly toward our knowledge of disease, furthering our mission of achieving personalized medicine,” said Robert B. Darnell, President and Scientific Director of NYGC.
Offering resources like the bio banking facility, RPCI will be able to assist the NYGC in learning about genetic origins and new treatments for cancer patients. The collaboration will also serve as a catalyst for important large-scale cancer genomic studies to be conducted at NYGC with other members.
Donald Trump, MD, President and CEO of Roswell Park Cancer Institute stated that “This partnership enhances our opportunities to extend collaborations with our colleagues throughout New York, including the New York City cancer centers, thus allowing us to bring the latest discoveries in genome science to our work to understand, prevent and cure cancer and other diseases.”
The collaboration opportunities that will come from this recent partnership will lead to resourceful and impactful research opportunities and clinical breakthroughs which will result in decreased health disparities of New York residents.